Yu Ding Email & Phone Number

Potomac, MD, US

Rockville, Maryland, US

• Orchestrate End-to-End S&E Initiatives, Develop strategic frameworks and best practices for evaluating novel targets, modalities, and enabling technologies across oncology, metabolic, and CNS disease areas..
• Drive Competitive Intelligence & Market Landscape Analysis, Oversee a competitive intelligence platform that tracks emerging science, competitor pipelines, and industry trends. Deliver regular, on-time competitor.
• Establish & Nurture Strategic Partnerships, Forge collaborations with top academic institutions, biotech start-ups, VCs, and government agencies, leading to several new collaborative research efforts and broadening.
• Manage External Collaborations, Oversee multiple R&D project partnerships, synchronizing timelines, resources, and deliverables across multidisciplinary teams. Streamline communication and alignment between Hansoh and.
• Influence Portfolio Prioritization, Present strategic insights to C-suite and senior leadership on pipeline gaps, competitor activities, and R&D investment strategies.
• Champion Innovation & Incubation, Conceive and roll out an internal incubation strategy to streamline the selection and early development of groundbreaking therapeutic concepts. Launched internal R&D “Innovation.

Rockville, Maryland, US

• Launched US R&D Operations, by setting up foundational research infrastructure, labs, and staffing plans.
• Pioneered Early Discovery Pipeline, leading interdisciplinary teams to develop preclinical candidates in oncology and metabolic indications.
• Forged Academic & Industrial Partnerships, defining strategies on collaborations for target validation and preclinical research.
• Partnered with Business Development, identify and integrate new targets into the company’s pipeline.

Seattle, WA, US

• Evaluated Commercial Potential of newly disclosed inventions, performed patent/literature searches, prior art analysis, and licensee outreach.
• Coordinated Technology Transfer, creating marketing materials and due diligence packages for partnering opportunities.

Seattle, WA, US

• Mammalian Surface Display Platform, for mid-sized peptide drug discovery, guiding hit-to-lead optimization in oncology and inflammatory diseases.
• Identify Commercialization Opportunities, aligning internal scientific expertise with external funding and strategic partnerships.
• Managed Cross-Functional Projects, integrating cutting-edge technology into preclinical studies.

Basel, Baselstadt, CH

• Head of functional genetics group, target identification and validation
• Lead Functional Genetics Team, in designing and executing in vitro/in vivo synthetic lethal screens for target discovery in oncology and liver disease.
• Pioneering High-Throughput CRISPR/Cas9 Platforms, to validate novel targets and biomarkers, supporting global R&D programs.
• Facilitated Cross-Site Collaboration, coordinating with disease area project teams in Asia and global Novartis research hubs.

Seattle, WA, US

• Target Discovery with Synthetic Lethality Screens, identify potential therapeutic target in Glioblastoma, with siRNA and CRISPR technologies.
• Developed Genome-Wide CRISPR Screens, to uncover therapeutic vulnerabilities in glioblastoma and pediatric brain tumors.
• Patient profiling and stratification using NGS analysis, for biomarker development and patient stratification.
• Carry out high throughput comparative studies, in adult and pediatric brain tumors to identify cancer specific targets and biomarkers.
• Target validation, cancer specific requirement of BUB1B/BUBR1, in human brain tumor cells.

Beijing, CN

• Identified Caprin-2 as a component of Wnt signaling pathway
• Designed and constructed human kinase and GEF shRNA libraries
• Helped developing shRNA reagent targeting SARS virus

Ph. D, Molecular And Cellular Biology

B.S, Biochemistry